FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.